Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US resident

Autor: Peter J. Neumann, James K. Hammitt, Hannah R. Auerbach, C Fang, David M. Kent, Joshua T. Cohen, Thomas W Concannon
Přispěvatelé: Tufts Medical Center, Tufts University, Economie des Ressources Naturelles (LERNA), Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Harvard University [Cambridge], Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Recherche Agronomique (INRA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Harvard University
Jazyk: francouzština
Rok vydání: 2012
Předmět:
Adult
Male
Financing
Personal
Cost-Benefit Analysis
predictive test
Breast Neoplasms
Disease
Choice Behavior
Risk Assessment
[SHS]Humanities and Social Sciences
03 medical and health sciences
Young Adult
0302 clinical medicine
Breast cancer
Willingness to pay
Alzheimer Disease
Risk Factors
Surveys and Questionnaires
Medicine
Humans
cancer
030212 general & internal medicine
Young adult
Predictive testing
B- ECONOMIE ET FINANCE
Aged
Aged
80 and over
Actuarial science
Cost–benefit analysis
business.industry
Diagnostic Tests
Routine
Health Policy
Prostatic Neoplasms
Middle Aged
medicine.disease
Health Surveys
United States
3. Good health
Test (assessment)
Logistic Models
arthritis
Respondent
Chronic Disease
alzheimer's disease
Female
business
willingness to pay
030217 neurology & neurosurgery
Demography
Zdroj: Health Economics
Health Economics, Wiley, 2012, 21 (3), pp.238-251. ⟨10.1002/hec.1704⟩
Health Economics, 2012, 21 (3), pp.238-251. ⟨10.1002/hec.1704⟩
ISSN: 1057-9230
1099-1050
DOI: 10.1002/hec.1704⟩
Popis: We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet-based survey to a random sample of adult US respondents. Each respondent answered questions about two different scenarios, each of which specified: one of four randomly selected diseases (Alzheimer's, arthritis, breast cancer, or prostate cancer); an ex ante risk of developing the disease (randomly designated 10 or 25%); and test accuracy (randomly designated perfect or 'not perfectly accurate'). Willingness-to-pay (WTP) was elicited with a double-bounded, dichotomous-choice approach. Of 1463 respondents who completed the survey, most (70-88%, depending on the scenario) were inclined to take the test. Inclination to take the test was lower for Alzheimer's and higher for prostate cancer compared with arthritis, and rose somewhat with disease prevalence and for the perfect versus imperfect test [Correction made here after initial online publication.]. Median WTP varied from $109 for the imperfect arthritis test to $263 for the perfect prostate cancer test. Respondents' preferences for predictive testing, even in the absence of direct treatment consequences, reflected health and non-health related factors, and suggests that conventional cost-effectiveness analyses may underestimate the value of testing.
Databáze: OpenAIRE
Externí odkaz: